Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma: a long-term retrospective analysis

References

• Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):1–13. doi: 10.1183/09031936.00202013.
   PubMed Web of Science ®Google Scholar
• Quirce S, Plaza V, Picado C, et al. Prevalence of uncontrolled severe persistent asthma in pneumology and allergy hospital units in Spain. J Investig Allergol Clin Immunol. 2011;21(6):466–471.
   PubMed Web of Science ®Google Scholar
• Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the severe asthma research program. Am J Respir Crit Care Med. 2010;181(4):315–323. doi: 10.1164/rccm.200906-0896OC.
   PubMed Web of Science ®Google Scholar
• Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008;178(3):218–224. doi: 10.1164/rccm.200711-1754OC.
   PubMed Web of Science ®Google Scholar
• Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012;18(5):716–725. doi: 10.1038/nm.2678.
   PubMed Web of Science ®Google Scholar
• Kulkarni NS, Hollins F, Sutcliffe A, et al. Eosinophil protein in airway macrophages: a novel biomarker of eosinophilic inflammation in patients with asthma. J Allergy Clin Immunol. 2010;126(1):61.e3–69.e3. doi: 10.1016/j.jaci.2010.03.026.
   Web of Science ®Google Scholar
• Pearce N, Pekkanen J, Beasley R. How much asthma is really attributable to atopy? Thorax. 1999;54(3):268–272. doi: 10.1136/thx.54.3.268.
   PubMed Web of Science ®Google Scholar
• Del Giacco SR, Bakirtas A, Bel E, et al. Allergy in severe asthma. Allergy. 2017;72(2):207–220. doi: 10.1111/all.13072.
   PubMed Web of Science ®Google Scholar
• Green RH, Brightling CE, Woltmann G, et al. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax. 2002;57(10):875–879. doi: 10.1136/thorax.57.10.875.
   PubMed Web of Science ®Google Scholar
• Papi A, Brightling C, Pedersen SE, et al. Asthma. Lancet. 2018;391(10122):783–800. doi: 10.1016/S0140-6736(17)33311-1.
   PubMed Web of Science ®Google Scholar
• Agache I, Beltran J, Akdis C, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020;75(5):1023–1042. doi: 10.1111/all.14221.
   PubMed Web of Science ®Google Scholar
• Charles D, Shanley J, Temple SN, et al. Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: a systematic review and meta-analysis. Clin Exp Allergy. 2022;52(5):616–627. doi: 10.1111/cea.14112.
   PubMed Web of Science ®Google Scholar
• Nagase H, Suzukawa M, Oishi K, et al. Biologics for severe asthma: the real-world evidence, effectiveness of switching, and prediction factors for the efficacy. Allergol Int. 2023;72(1):11–23. doi: 10.1016/j.alit.2022.11.008.
   PubMed Web of Science ®Google Scholar
• Ledford D, Busse W, Trzaskoma B, et al. A randomized multicenter study evaluating xolair persistence of response after long-term therapy. J Allergy Clin Immunol. 2017;140(1):162–169.e2. doi: 10.1016/j.jaci.2016.08.054.
   PubMed Web of Science ®Google Scholar
• Riccardi E, Guida G, Garino S, et al. “Head-to-head” comparison between biologics in severe asthma: a real-world study. Eur Respir J. 2023; 62:PA4739. doi: 10.1183/13993003.congress-2023.PA4739.
   Google Scholar
• Global Initiative for Asthma. Global strategy for asthma management and prevention. 2023 [cited 2023 July 15]. https://www.ginaasthma.org
   Google Scholar
• Jia CE, Zhang HP, Lv Y, et al. The asthma control test and asthma control questionnaire for assessing asthma control: systematic review and meta-analysis. J Allergy Clin Immunol. 2013;131(3):695–703. doi: 10.1016/j.jaci.2012.08.023.
   PubMed Web of Science ®Google Scholar
• Kavanagh JE, Hearn AP, Dhariwal J, et al. Real-world effectiveness of benralizumab in severe eosinophilic asthma. Chest. 2021;159(2):496–506. doi: 10.1016/j.chest.2020.08.2083.
   PubMed Web of Science ®Google Scholar
• Javier Álvarez-Gutiérrez F, Blanco-Aparicio M, Plaza V, et al. G. Consensus document for severe asthma in adults. Open Respir Arch. 2020;2(3):158–174.
   Google Scholar
• Plaza Moral V, Alobid I, Álvarez Rodríguez C, et al. GEMA 5.3. Spanish guideline on the management of asthma. Open Respir Arch. 2023;5(4):100277. doi: 10.1016/j.opresp.2023.100277.
   PubMedGoogle Scholar
• Travers J, Marsh S, Williams M, et al. External validity of randomised controlled trials in asthma: to whom do the results of the trials apply? Thorax. 2007;62(3):219–223. doi: 10.1136/thx.2006.066837.
   PubMed Web of Science ®Google Scholar
• Harrison T, Canonica GW, Chupp G, et al. Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis. Eur Respir J. 2020;56(4):2000151. doi: 10.1183/13993003.00151-2020.
   PubMed Web of Science ®Google Scholar
• Martínez-Moragón E, García-Moguel I, Nuevo J, et al. Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study). BMC Pulm Med. 2021;21(1):417. doi: 10.1186/s12890-021-01785-z.
   PubMed Web of Science ®Google Scholar
• Pelaia C, Calabrese C, Terracciano R, et al. Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness. Dec. Ther Adv Respir Dis. 2018;12:1753466618810192. doi: 10.1177/1753466618810192.
   Web of Science ®Google Scholar
• Di Bona D, Fiorino I, Taurino M, et al. Long-term “real-life” safety of omalizumab in patients with severe uncontrolled asthma: a nine-year study. Respir Med. 2017;130:55–60. doi: 10.1016/j.rmed.2017.07.013.
   PubMed Web of Science ®Google Scholar
• Frix AN, Schleich F, Paulus V, et al. Effectiveness of omalizumab on patient reported outcomes, lung function, and inflammatory markers in severe allergic asthma. Biochem Pharmacol. 2020;179:113944. doi: 10.1016/j.bcp.2020.113944.
   PubMed Web of Science ®Google Scholar
• Bhutani M, Yang WH, Hébert J, et al. The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: the ASTERIX observational study. PLOS One. 2017;12(8):e0183869. doi: 10.1371/journal.pone.0183869.
   PubMed Web of Science ®Google Scholar
• Casas-Maldonado F, Baynova K, Soto-Campos G, et al. EXACTO scale: multidimensional tool for assessing the response to treatment with monoclonal antibodies in severe uncontrolled asthma. EACCI Hybrid Congres. 2022.
   Google Scholar
• Pérez de Llano L, Davila I, Martinez-Moragon E, et al. Development of a tool to measure the clinical response to biologic therapy in uncontrolled severe asthma: the FEV1, exacerbations, oral corticosteroids symptoms score. J Allergy Clin Immunol Pract. 2021;9(7):2725–2731. doi: 10.1016/j.jaip.2021.01.033.
   PubMed Web of Science ®Google Scholar
• Thomas D, McDonald VM, Pavord ID, et al. Asthma remission: what is it and how can it be achieved? Eur Respir J. 2022;60(5):2102583. doi: 10.1183/13993003.02583-2021.
   PubMed Web of Science ®Google Scholar
• Upham JW, Le Lievre C, Jackson DJ, et al. Defining a severe asthma super-responder: findings from a Delphi process. J Allergy Clin Immunol Pract. 2021;9(11):3997–4004. doi: 10.1016/j.jaip.2021.06.041.
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Bafadhel M, Busse WW, et al. An expert consensus framework for asthma remission as a treatment goal. J Allergy Clin Immunol. 2020;145(3):757–765. doi: 10.1016/j.jaci.2019.12.006.
   PubMed Web of Science ®Google Scholar
• Padró-Casas P, Basagaña M, Rivera Ortún ML, et al. Characterization and factors associated with poor asthma control in adults with severe eosinophilic asthma. J Pers Med. 2023;13(7):1173. doi: 10.3390/jpm13071173.
   PubMed Web of Science ®Google Scholar
• Taillé C, Pison C, Nocent C, et al. Patients in the IDEAL cohort: a snapshot of severe asthma in France. Rev Mal Respir. 2019;36(2):179–190. doi: 10.1016/j.rmr.2018.10.005.
   PubMed Web of Science ®Google Scholar
• Buhl R, Korn S, Menzies-Gow A, et al. Assessing biomarkers in a real-world severe asthma study (ARIETTA). Respir Med. 2016;115:7–12. doi: 10.1016/j.rmed.2016.04.001.
   PubMed Web of Science ®Google Scholar
• Calhoun WJ, Haselkorn T, Mink DR, et al. Clinical burden and predictors of asthma exacerbations in patients on guideline-based steps 4-6 asthma therapy in the TENOR cohort. J Allergy Clin Immunol Pract. 2014;2(2):193–200. doi: 10.1016/j.jaip.2013.11.013.
   PubMed Web of Science ®Google Scholar
• Drick N, Milger K, Seeliger B, et al. Switch from IL-5 to IL-5-receptor α antibody treatment in severe eosinophilic asthma. J Asthma Allergy. 2020;13:605–614. doi: 10.2147/JAA.S270298.
   PubMed Web of Science ®Google Scholar
• Kavanagh JE, Hearn AP, d’Ancona G, et al. Benralizumab after sub-optimal response to mepolizumab in severe eosinophilic asthma. Allergy. 2021;76(6):1890–1893. doi: 10.1111/all.14693.
   PubMed Web of Science ®Google Scholar
• Mümmler C, Munker D, Barnikel M, et al. Dupilumab improves asthma control and lung function in patients with insufficient outcome during previous antibody therapy. J Allergy Clin Immunol Pract. 2021;9(3):1177.e4–1185.e4. doi: 10.1016/j.jaip.2020.09.014.
   Google Scholar
• Numata T, Araya J, Miyagawa H, et al. Real-world effectiveness of dupilumab for patients with severe asthma: a retrospective study. J Asthma Allergy. 2022;15:395–405. doi: 10.2147/JAA.S357548.
   PubMed Web of Science ®Google Scholar